Status:
COMPLETED
Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM
Lead Sponsor:
Haseki Training and Research Hospital
Conditions:
Gestational Diabetes
Eligibility:
FEMALE
18-42 years
Brief Summary
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabet...
Detailed Description
The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabet...
Eligibility Criteria
Inclusion
- Maternal age between 18 and 42 years
- Gestational age between 20 and 28 weeks
Exclusion
- Multiple pregnancies
- Pregestational diabetes
- Fetal congenital malformations
- Placental and amniotic fluid abnormalities
- Preeclampsia
- Severe systemic disease
- Long-term systemic drug usage
Key Trial Info
Start Date :
February 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 10 2022
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT05392231
Start Date
February 10 2022
End Date
May 10 2022
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haseki Training and Research Hospital
Istanbul, Turkey (Türkiye)